Comparative Screening of K-ras Mutations in Colorectal Cancer and Lung Cancer Patients Using a Novel Real-Time PCR with ADx-K-ras Kit and Sanger DNA Sequencing

2011 ◽  
Vol 62 (3) ◽  
pp. 415-420 ◽  
Author(s):  
Haiping Zhang ◽  
Xiongwei Zheng ◽  
Tianhai Ji ◽  
Li Fu ◽  
Dongyu Bai ◽  
...  
2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e22100-e22100
Author(s):  
Chi-Kuan Chen

e22100 Background: Identifying K-ras mutation has became a standard procedure in cancer treatment. Colorectal cancer patients with K-ras mutation are likely to poorly respond to cetuximab. Therefore, detecting K-ras gene mutations should be suggested before the selection of personalized treatment in colorectal cancer. To date, general molecular biology techniques contain HRM, PCR-RFLP, TaqMan PCR and CE-IVD-validated Cobas 4800 KRAS (Roche Diagnostics) are used for K-ras mutation detection in molecular diagnosis, but the sensitivity limitation of these method is approximately 1%. Methods: Therefore, we used a new approach, a universal genetic detecting method (FemtoPath), which improves sensitivity of K-ras mutation detection and the limitation of sensitivity is closed to 0.1% of mutation type. Results: We compared the sensitivity between FemtoPath/direct sequencing test and Cobas KRAS real-time PCR. Cobas real-time PCR identifies mutations in 21 (40.38%) of the 52 tumors. Surprisingly, the FemtoPath/direct sequencing test identified mutations in 40 (76.92%) of the 52 tumors. Our data showed that the FemtoPath/direct sequencing test can identify 19 additional mutation samples. In addition, the FemtoPath/direct sequencing test can identify more unknown K-ras mutations adjacent to codon 12 and 13. Conclusions: Ensure the most timely and appropriate therapy for cancer patients is the first priority of clinical application. FemtoPath/direct sequencing test is more sensitive, accurate and inexpensive and needs fewer sample amount than Cobas real-time PCR.


2017 ◽  
Vol 28 ◽  
pp. v36
Author(s):  
P. Taniere ◽  
P. Taniere ◽  
M. Smith ◽  
B. O'Sullivan ◽  
F. Hughes ◽  
...  

2009 ◽  
Vol 29 (3) ◽  
pp. 249-255 ◽  
Author(s):  
Jeong-Man Kim ◽  
Sang Hyun Hwang ◽  
Eun Ju Song ◽  
Lee Sang-Yull ◽  
Yeong-Dae Kim ◽  
...  

2009 ◽  
Vol 14 (Suppl 4) ◽  
pp. 237 ◽  
Author(s):  
A Szpechcinski ◽  
M Dancewicz ◽  
P Kopinski ◽  
J Kowalewski ◽  
J Chorostowska-Wynimko

1969 ◽  
Vol 40 (2) ◽  
pp. 148-157
Author(s):  
Edward F. Carrillo ◽  
Yazmín Rocío Arias ◽  
Sandra J. Perdomo ◽  
Fabio Ancízar Aristizábal ◽  
Paulina Ojeda ◽  
...  

Introduction: In spite of recent treatment advances, lung cancer continues to be the first world cancer related death cause; its mortality associated occupied the fifth place in Colombia in 2004. Complete surgical resection is the therapeutic option with the greatest cure probability, however it results frequently ineffective given the current incapacity in Colombia to an early detection of the disease. This study reports the characterization of a group of 30 lung cancer patients regarding the gene dose (gene copy number) found at the loci corresponding to genes EGFR (erb B1), PIK3CA and C-myc in tumor samples, and compares the results with the dose found in adjacent lung from the same patients. Methods: The gene dose of EGFR (erbB1), PIK3CA, and C-myc were measured by real time PCR in matched tumor and normal lung tissue samples. Results are expressed as the multiplicity of each gene dose with respect to a single copy reference gene. In this case the gene HHB (human hemoglobin). Antiquity of the cases ranged from 5 to 10 years. Results: An increased gene dose for EGFR and PIK3CA was a feature clearly associated to the tumor phenotype of the sample (found in 96 and 100% of the tumors respectively). Quantitative measure of this feature demonstrated for both genes a high sensitivity and specificity for tumor/normal discrimination as confirmed by the ROC analysis. On the other hand, the Spearman test showed a great correlation between EGFR and PIK3CA doses (r=0.75). C-myc was the gene whose dose was less consistently correlated to the tumor phenotype, however most of the patients with amplified C-myc presented distant spread of tumor cells (metastasis) at diagnosis. Conclusion: Quantitative measurement of EGFR, PIK3CA, and C-myc gene dose by real time PCR provides a method for tumor phenotype recognition in DNA samples from lung tissue. These markers can be considered at the construction of a marker panel for lung cancer detection on alternative, non-invasive clinical samples. However clinical value will depend on the use of additional molecular markers, some of which could be of epigenetic character.


2007 ◽  
Vol 2 (8) ◽  
pp. S815
Author(s):  
Jinsung Jang ◽  
Myunghwa Chae ◽  
Myunghoon Lee ◽  
Eungbae Lee ◽  
Taein Park ◽  
...  

2014 ◽  
Vol 23 (01n02) ◽  
pp. 1450011
Author(s):  
Ahmad Abushakra ◽  
Miad Faezipour

Virtual reality technology is an attractive means for medical simulations and treatment, especially for patients with cancer. The overall goal of this research is to introduce a conceptual virtual environment with real-world dynamic contents to develop an effective breathing exercise tool that will aid in regulating breathing movements and eventually increase the oxygen intake of users/patients. This study focuses on an essential component of the virtual reality therapy framework. The work introduces a novel automated approach towards computing the lung capacity. The overall objective is to aid lung cancer patients, or those with breathing disorders regulate their breath through real-time analysis of respiration movements using a smart-phone. Traditionally, lung cancer patients and those with certain breathing disorders use a spirometer device to measure their lung capacity. However, accurate measurements using the spirometer requires some sort of training and adjustment, which may be difficult for certain groups of patients, especially the elderly. In this paper, a methodology is proposed to process the recorded acoustic signal of respiration using a microphone, and a model is introduced to estimate the lung size with a high degree of accuracy. To estimate the lung capacity, Voice-Activity-Detection (VAD) is fine-tuned and applied to the acoustic signal of respiration to split the signal into voice and silence phases. The average time duration and energy of the breathing phases (inhale and exhale voice phases) are computed to derive the lung capacity. The signal processing relies on accurate signal segmentation and signal energy computation of the breathing cycles. This model of using a microphone and the acoustic signal of respiration to estimate lung capacity yields a high degree of accuracy, exceeding 85%. In the framework, lung capacity is computed simultaneously as the patient is breathing in real time. Consequently, the patient will be motivated to take the next coming breath deeply if the previous one was not sufficient, thus, virtually regulating his/her own breath. The results indicate that the proposed model is highly accurate and effective for estimating lung capacity. The potential outcome of this research is that the intended virtual reality framework, if fully implemented and integrated with a high quality animated application on a smart-phone, would directly aid individuals, especially lung cancer patients, regulate their breath by having a daily basis estimate of their lung size using a hand-held device at home.


Sign in / Sign up

Export Citation Format

Share Document